Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Monitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.

< BACK TO ARCHIVE


2022 Jul 01


J Infect Dis


http://www.ncbi.nlm.nih.gov/pubmed/35776140?dopt=Abstract

Monitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.

Authors

Monitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
Nyombayire J, Ingabire R, Magod B, Mazzei A, Mazarati J B, Noben J, Katwere M, Parker R, Nsanzimana S, Wall KM, Sayinzoga F, Tichacek A, Robinson C, Hammoud N, Priddy F, Allen S, Karita E
J Infect Dis. 2022 Jul 01.
PMID: 35776140.

Abstract

From 2019-2021, Rwandan residents of the border with Democratic Republic of the Congo were offered the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.
Read This Paper